A detailed history of Wells Fargo & Company transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 12,003 shares of VERA stock, worth $579,864. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,003
Previous 12,478 3.81%
Holding current value
$579,864
Previous $451,000 17.52%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$34.09 - $46.71 $16,192 - $22,187
-475 Reduced 3.81%
12,003 $530,000
Q2 2024

Aug 13, 2024

SELL
$33.72 - $48.82 $22,693 - $32,855
-673 Reduced 5.12%
12,478 $451,000
Q1 2024

May 10, 2024

BUY
$14.91 - $49.14 $52,468 - $172,923
3,519 Added 36.53%
13,151 $567,000
Q4 2023

Feb 09, 2024

SELL
$9.29 - $16.0 $211,542 - $364,336
-22,771 Reduced 70.27%
9,632 $148,000
Q3 2023

Nov 13, 2023

BUY
$13.71 - $19.64 $259,941 - $372,374
18,960 Added 141.04%
32,403 $444,000
Q2 2023

Aug 15, 2023

BUY
$6.11 - $17.83 $56,431 - $164,677
9,236 Added 219.54%
13,443 $215,000
Q1 2023

May 12, 2023

BUY
$5.41 - $18.3 $22,759 - $76,988
4,207 New
4,207 $32,000
Q3 2022

Nov 14, 2022

SELL
$13.27 - $22.31 $1,486 - $2,498
-112 Reduced 32.65%
231 $5,000
Q2 2022

Aug 12, 2022

SELL
$12.82 - $23.4 $33,485 - $61,120
-2,612 Reduced 88.39%
343 $5,000
Q1 2022

May 16, 2022

SELL
$17.8 - $28.06 $48,807 - $76,940
-2,742 Reduced 48.13%
2,955 $69,000
Q4 2021

Feb 14, 2022

BUY
$15.01 - $35.8 $84,806 - $202,269
5,650 Added 12021.28%
5,697 $152,000
Q3 2021

Nov 15, 2021

BUY
$13.71 - $30.6 $260 - $581
19 Added 67.86%
47 $1,000
Q2 2021

Aug 16, 2021

BUY
$11.5 - $19.97 $322 - $559
28 New
28 $0

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.31B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Wells Fargo & Company Portfolio

Follow Wells Fargo & Company and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.